UroGen Pharma price target raised to $53.50 from $48 at Ladenburg

Ladenburg analyst Matthew Kaplan raised the firm’s price target on UroGen Pharma to $53.50 from $48 and keeps a Buy rating on the shares based on lowering the discount rate applied for UGN-102 based on the ENVISION DoR update. UroGen Pharma announced 82.3% 12-month duration of response, or DoR, data that was “strong,” notes the analyst, who points out that UroGen expects an Advisory Committee meeting with potential approval by Q1 of 2025 with priority review and Q2 of 2025 with standard review.